1. Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review
   Navami Prabhakar Koyande et al, 2022, Vaccines CrossRef
2. CD4 and CD8 T lymphocyte interplay in controlling tumor growth
   Dmitrij Ostroumov et al, 2018, Cellular and Molecular Life Sciences CrossRef
3. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer
   Oscar Arrieta et al, 2020, JAMA Oncology CrossRef
4. The promise of Immuno-oncology: implications for defining the value of cancer treatment
   Howard L. Kaufman et al, 2019, Journal for ImmunoTherapy of Cancer CrossRef
5. Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non–Small Cell Lung Cancer in US Clinical Practice
   Mary K. Nesline et al, 2020, Clinical Therapeutics CrossRef
6. CT-based radiomics models may predict the early efficacy of microwave ablation in malignant lung tumors
   Fandong Zhu et al, 2023, Cancer Imaging CrossRef
7. Older Cancer Patients during the COVID-19 Epidemic: Practice Proposal of the International Geriatric Radiotherapy Group
   Nam P. Nguyen et al, 2020, Cancers CrossRef
8. Predictive value of baseline metabolic tumor volume for non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
   Ke Zhu et al, 2022, Frontiers in Oncology CrossRef
9. Real-World Immunotherapy Use and Effectiveness in Advanced NSCLC With Programmed Death-Ligand 1 Greater Than or Equal to 50% and Greater Than or Equal to 90%
   Ashley Jackson et al, 2023, JTO Clinical and Research Reports CrossRef
10. Impact of Center Volume on Cardiopulmonary and Mortality Outcomes after Immune-Checkpoint Inhibitors for Cancer: A Systematic Review and Meta-Analysis
    Mohamed Rahouma et al, 2024, Cancers CrossRef
11. Formulation strategies in immunotherapeutic pharmaceutical products
    Yajie Zhang et al, 2020, World Journal of Clinical Oncology CrossRef
12. Gene-based Interventions for Cancer Immunotherapy
    Otto L.D. Cerqueira et al, 2019, In Vivo and Ex Vivo Gene Therapy for Inherited and Non-Inherited Disorders CrossRef
13. Cancer Immunoprevention: Current Status and Future Directions
    Mahsa Keshavarz-Fathi et al, 2021, Archivum Immunologiae et Therapiae Experimentalis CrossRef
14. Experience of patients considering or using checkpoint inhibitors in cancer treatment: a systematic review of qualitative research
    Raphael Yip et al, 2024, Journal for ImmunoTherapy of Cancer CrossRef
15. The nutrition‐related adverse events associated with immune checkpoint inhibitor treatment for patients with non‐small cell lung cancer: A systematic review
    Kate L. Graham et al, 2024, Nutrition & Dietetics CrossRef
16. Immunotherapy in the Battle Against Bone Metastases: Mechanisms and Emerging Treatments
    Fatheia N. Hamza et al, 2024, Pharmaceuticals CrossRef
17. Bronchoalveolar Lavage Fluid-Isolated Biomarkers for the Diagnostic and Prognostic Assessment of Lung Cancer
    Alexandros Kalkanis et al, 2022, Diagnostics CrossRef
18. Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition
    Ken Kudura et al, 2023, Journal of Clinical Medicine CrossRef
19. The involvement of Lymphocyte activation gene 3 and the inhibitor in non-small cell lung cancer
    Rongxiang Lin, 2023, Highlights in Science, Engineering and Technology CrossRef
20. nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
    Corey J. Langer et al, 2021, Frontiers in Oncology CrossRef